X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
NYPRG-101, also referred to in the literature as BOL-148 (2-bromo-d-lysergic acid diethylamide), is a non-hallucinogenic analog of LSD, differing by only one atom. It is currently in phase 1 clinical trial for migraine and cluster headache.
Lead Product(s): 2-Bromo-Lysergic Acid Diethylamide
Therapeutic Area: Neurology Product Name: BOL-148
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 17, 2023
Details:
The primary endpoint of the trial is to determine the reduction in OCD symptoms for up to 12 weeks after a single administration of SYNP-101 (psilocybin).
Lead Product(s): Psilocybine
Therapeutic Area: Psychiatry/Psychology Product Name: SYNP-101
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Yale School of Medicine
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2022
Details:
NYPRG-101 (2-bromo-D-lysergic acid diethylamide), referred as BOL-148, is a non-hallucinogenic analog of LSD. Results from IND-enabling pre-clinical toxicology work as well as research conducted with human subjects, indicate a positive safety profile for NYPRG-101.
Lead Product(s): 2-Bromo-Lysergic Acid Diethylamide
Therapeutic Area: Neurology Product Name: NYPRG-101
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 21, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
